COMPASS THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
COMPASS THERAPEUTICS, INC. (CMPX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $3.46 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $3.46.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $3.31.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $3.38.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $3.39.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $3.46 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.31 10-Q · filed 2026-05-05 |
| 2025-12-31 | $3.38 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.39 10-Q · filed 2025-11-05 |
| 2025-06-30 | $3.46 10-Q · filed 2025-08-11 |
| 2025-03-31 | $3.55 10-Q · filed 2025-05-08 |
| 2024-12-31 | $3.67 10-K · filed 2025-02-27 |
| 2024-09-30 | $3.82 10-Q · filed 2024-11-12 |
| 2024-06-30 | $3.95 10-Q · filed 2024-08-12 |
| 2024-03-31 | $4.10 10-Q · filed 2024-05-13 |
| 2023-12-31 | $4.22 10-K · filed 2024-03-21 |
| 2023-09-30 | $4.28 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.34 10-Q · filed 2023-08-03 |
| 2023-03-31 | $4.45 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.65 10-K · filed 2023-03-15 |
| 2022-09-30 | $4.74 10-Q · filed 2022-11-09 |
| 2022-06-30 | $4.86 10-Q · filed 2022-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |